Phase 2 N=180 Photodynamic Therapy in Treating Patients With Skin Cancer
Non-melanomatous Skin Cancer · Precancerous Condition
Primary: Response Rate
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=96 Vitamin D Repletion in Coronary Artery Disease
Vitamin D Deficiency · Coronary Artery Disease · Endothelial Dysfunction
Primary: Endothelial Function — 0.13; -0.04 reactive hypermia index
Phase 3 N=402 Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
Refractory Partial Epilepsy
Primary: Part I: Seizure Frequency — 7.64; 6.73; 5.66; 5.35 ln (Seizures) per 4 weeks
Phase 3 N=1,224 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Prostatic Neoplasms · Neoplasm Metastasis
Primary: Overall Survival Time — 21.22; 22.14 months — p=0.3802
Phase 3 N=200 (A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
Coronary Artery Disease
Primary: Major Adverse Cardiac Events — 2 percentage of event
Phase 2 N=17 Replagal Enzyme Replacement Therapy for Children With Fabry Disease
Fabry Disease
Primary: Patients Who Experienced At Least One Adverse Event (AE) — 17 participants
Phase 3 N=595 A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
Crohn's Disease
Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study CDP870-033 (up to 84 Months) — 88.2 percentage of subjects
Phase 3 N=87 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary Incontinence
Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day
Phase 3 N=402 Maintaining Nonsmoking: Older Smokers - 1
Tobacco Use Disorder
Primary: Participants Abstinent From Cigarettes — 31; 35; 39; 45 participants
N/A N=126 A Five-Year Metal-on-Metal Retrospective Clinical Study
Osteoarthritis
Primary: Metal Ion Levels Per Participant — 1.4; 2.1 micrograms per liter
Phase 2 N=229 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Vulvovaginal Candidiasis
Primary: Dose-response of Clinical and Mycological (Global) Therapeutic Response — 31.7; 48.7; 47.6; 53.8 percentage of patients cured — p=0.0630
N/A N=8 Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™
Cystinosis · Nephropathic Cystinosis
Primary: Cysteamine Absorption: Area Under the Plasma Concentration Curve (AUC) — 3618; 2799; 2457 min*uM — p=.04
Phase 2 N=55 Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
Breast Cancer · Metastatic Cancer
Primary: Central Nervous System (CNS) Progression-free Survival(PFS) — 12; 2 participants
N/A N=734 Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)
Psoriasis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Serious Adverse Drug Reactions (SADRs), Deaths, and…
Phase 2 N=81 Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) of Iloperidone Divided by the Average Plasma Concentration (Cav) of Iloperidone (Cmax/Cav) - Phase B — 1.91; 1.87 Ratio of…